Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295258 | 0.88 | LTA4H (0.35) | ABL1P2RY14LTA4HQPCT | |
| SCHEMBL22440199 | 0.88 | MAPT (0.40) | PIK3CAMAPTABL1P2RY14KDM4E | |
| SCHEMBL22440207 | 0.84 | MAPT (0.53) | PIK3CAMAPTABL1KDM4EQPCT | |
| SCHEMBL30770890 | 0.84 | QPCT (0.36) | PIK3CAMAPTABL1P2RY14KDM4E | |
| SCHEMBL21295277 | 0.84 | QPCT (0.36) | PIK3CAMAPTABL1P2RY14KDM4E | |
| SCHEMBL21303604 | 0.82 | ABL1 (0.40) | MAPTABL1P2RY14LTA4HKDM4E | |
| SCHEMBL22440183 | 0.80 | QPCT (0.47) | MAPTP2RY14KDM4EDHFRQPCT | |
| SCHEMBL22440192 | 0.79 | DHFR (0.51) | PIK3CADHFRQPCT | |
| SCHEMBL22440191 | 0.75 | QPCT (0.49) | ABL1QPCT | |
| SCHEMBL22440185 | 0.75 | MAPT (0.54) | MAPTKDM4EQPCTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | disclosed |
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-3589632-B1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019162458-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392174-A1 | NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES | GMPS, GLS, QPCT | PIK3CA 2620/4885MAPT 4289/4885ABL1 3351/4885 |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | PIK3CA 2568/4885MAPT 4117/4885ABL1 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.